Amgen

Open: 269.41 Close: 265.39 Change: -4.02

How to get informed about Amgen Stock quickly using an AI.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, announce, Inc, recently, company, Amgens, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. recently announced a dividend of $2.13 per share, payable on 2023-12-08, with the ex-dividend date set for 2023. The biopharma company recently announced its third round of layoffs.

Today's News

US-based biotech PostEra has partnered with Amgen for a multi-target collaboration in drug discovery. The companies will use PostEras artificial intelligence platform Proton and Amgens expertise in drug development. Amgen announces new data reinforcing safety and efficacy of Repatha (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIERS-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023. The Senior Manager will be the systems and process expert for Amgens warehousing systems and sub-systems. This role is also responsible for identifying, establishing, modeling, and monitoring key performance measures. Amgen Inc. recently announced a dividend of $2.13 per share, payable on 2023-12-08, with the ex-dividend date set for 2023. Zacks.com users have recently been watching Amgen (AMGN) quite a bit. The biopharma company recently announced its third round of layoffs. Lisa Shamon, Ph.D., as Vice President of Regulatory Affairs and Xianne Leong Penny, Ph., as Senior Medical Director. Shamon held several regulatory affairs positions at various companies, including Alza Corporation. Amgen Inc. has a strong financial record characterized by robust revenue from its various therapies and sustained investment in research and development. Future is intricately linked with the advancement of biotechnological research. Amgen Inc.s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. Amgen earlier this month acquired Horizon Therapeutics for $27.8 billion. Federal Trade Commission (FTC) has reached a settlement with the biopharmaceutical corporation Amgen, paving the way for a $27.8 billion acquisition of Horizon Therapeutics. The settlement comes with some restrictions on Amgens future behavior but the acquisition may expose Amgen to legal claims currently being filed against Horizon. Amgen Inc. is listed as having around 500 people on LinkedIn. Amgen recently announced a $27.8 billion buyout of Horizon, Amgen is laying off 350 former Horizon employees. Amgen Inc. (NASDAQ:AMGN) Q3 2023 Earnings Call Transcript (Insider Monkey)

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, announce, Inc, recently, company, Amgens, and the most common words in the summary are: amgen, job, stock, market, pdf, kb, inc, . One of the sentences in the summary was: Amgen Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #job #stock #market #pdf #kb #inc.